Bruce E. Johnson, MD

Author Correction: Comprehensive genomic characterization of HER2-low and HER2-0 breast cancer. Nat Commun. 2023 Dec 14; 14(1):8321. View in: Pubmed

Ultrasensitive Detection of Circulating LINE-1 ORF1p as a Specific Multicancer Biomarker. Cancer Discov. 2023 Dec 12; 13(12):2532-2547. View in: Pubmed

Artificial intelligence-powered assessment of pathologic response to neoadjuvant atezolizumab in patients with non-small cell lung cancer: results from the LCMC3 study. J Thorac Oncol. 2023 Dec 07. View in: Pubmed

Canakinumab Versus Placebo in Combination With First-Line Pembrolizumab Plus Chemotherapy for Advanced Non-Small-Cell Lung Cancer: Results From the CANOPY-1 Trial. J Clin Oncol. 2023 Dec 01; JCO2300980. View in: Pubmed

Comprehensive genomic characterization of HER2-low and HER2-0 breast cancer. Nat Commun. 2023 11 18; 14(1):7496. View in: Pubmed

Multi-institutional analysis of aneuploidy and outcomes to chemoradiation and durvalumab in stage III non-small cell lung cancer. J Immunother Cancer. 2023 Nov; 11(11). View in: Pubmed

Author Correction: Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial. Nat Med. 2023 Oct 10. View in: Pubmed

Impact of TMB/PD-L1 expression and pneumonitis on chemoradiation and durvalumab response in stage III NSCLC. Nat Commun. 2023 07 15; 14(1):4238. View in: Pubmed

A cellular and spatial atlas of TP53 -associated tissue remodeling in lung adenocarcinoma. bioRxiv. 2023 Jun 29. View in: Pubmed

Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With BRAFV600-Mutant Metastatic Non-Small-Cell Lung Cancer. J Clin Oncol. 2023 07 20; 41(21):3700-3711. View in: Pubmed

Impact of Aneuploidy and Chromosome 9p Loss on Tumor Immune Microenvironment and Immune Checkpoint Inhibitor Efficacy in NSCLC. J Thorac Oncol. 2023 11; 18(11):1524-1537. View in: Pubmed

Ultrasensitive detection of circulating LINE-1 ORF1p as a specific multi-cancer biomarker. bioRxiv. 2023 Mar 17. View in: Pubmed

Tumor Volume Nadir in Patients With ALK-Rearranged Non-Small-Cell Lung Cancer Treated With Alectinib. JCO Precis Oncol. 2023 03; 7:e2200603. View in: Pubmed

Acquiring tissue for advanced lung cancer diagnosis and comprehensive biomarker testing: A National Lung Cancer Roundtable best-practice guide. CA Cancer J Clin. 2023 Jul-Aug; 73(4):358-375. View in: Pubmed

Clinicopathologic and Genomic Factors Impacting Efficacy of First-Line Chemoimmunotherapy in Advanced NSCLC. J Thorac Oncol. 2023 06; 18(6):731-743. View in: Pubmed

Features of tumor-microenvironment images predict targeted therapy survival benefit in patients with EGFR-mutant lung cancer. J Clin Invest. 2023 01 17; 133(2). View in: Pubmed

Rare FGFR Oncogenic Alterations in Sequenced Pediatric Solid and Brain Tumors Suggest FGFR Is a Relevant Molecular Target in Childhood Cancer. JCO Precis Oncol. 2022 Nov; 6:e2200390. View in: Pubmed

Surgical results of the Lung Cancer Mutation Consortium 3 trial: A phase II multicenter single-arm study to investigate the efficacy and safety of atezolizumab as neoadjuvant therapy in patients with stages IB-select IIIB resectable non-small cell lung cancer. J Thorac Cardiovasc Surg. 2023 03; 165(3):828-839.e5. View in: Pubmed

MatchMiner: an open-source platform for cancer precision medicine. NPJ Precis Oncol. 2022 Oct 06; 6(1):69. View in: Pubmed

Safety of image guided research biopsies in patients with thoracic malignancies. Lung Cancer. 2022 11; 173:53-57. View in: Pubmed

Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial. Nat Med. 2022 10; 28(10):2155-2161. View in: Pubmed

Identification and Management of Pathogenic Variants in BRCA1, BRCA2, and PALB2 in a Tumor-Only Genomic Testing Program. Clin Cancer Res. 2022 06 01; 28(11):2349-2360. View in: Pubmed

State legislative trends related to biomarker testing. Cancer. 2022 08 01; 128(15):2865-2870. View in: Pubmed

Serological testing for SARS-CoV-2 antibodies of employees shows low transmission working in a cancer center. PLoS One. 2022; 17(4):e0266791. View in: Pubmed

Clinical Outcomes With Dabrafenib Plus Trametinib in a Clinical Trial Versus Real-World Standard of Care in Patients With BRAF-Mutated Advanced NSCLC. JTO Clin Res Rep. 2022 May; 3(5):100324. View in: Pubmed

Response to Hopkins, Kichenadasse, Logan, et al. J Natl Cancer Inst. 2022 03 08; 114(3):477-478. View in: Pubmed

Real-World Analysis of Off-Label Use of Molecularly Targeted Therapy in a Large Academic Medical Center Cohort. JCO Precis Oncol. 2022 01; 6:e2100232. View in: Pubmed

Encorafenib plus binimetinib in patients with BRAFV600-mutant non-small cell lung cancer: phase II PHAROS study design. Future Oncol. 2022 Mar; 18(7):781-791. View in: Pubmed

Defining comprehensive biomarker-related testing and treatment practices for advanced non-small-cell lung cancer: Results of a survey of U.S. oncologists. Cancer Med. 2022 01; 11(2):530-538. View in: Pubmed

Microenvironment drives cell state, plasticity, and drug response in pancreatic cancer. Cell. 2021 12 09; 184(25):6119-6137.e26. View in: Pubmed

Smoking History as a Potential Predictor of Immune Checkpoint Inhibitor Efficacy in Metastatic Non-Small Cell Lung Cancer. J Natl Cancer Inst. 2021 Nov 29; 113(12):1761-1769. View in: Pubmed

Germline Testing Data Validate Inferences of Mutational Status for Variants Detected From Tumor-Only Sequencing. JCO Precis Oncol. 2021; 5. View in: Pubmed

Postdiagnosis BMI Change Is Associated with Non-Small Cell Lung Cancer Survival. Cancer Epidemiol Biomarkers Prev. 2022 01; 31(1):262-268. View in: Pubmed

The Impact of COVID-19 on Clinical Trial Execution at the Dana-Farber Cancer Institute. J Natl Cancer Inst. 2021 11 02; 113(11):1453-1459. View in: Pubmed

Tumor Growth Rate After Nadir Is Associated With Survival in Patients With EGFR-Mutant Non-Small-Cell Lung Cancer Treated With Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor. JCO Precis Oncol. 2021 11; 5:1603-1610. View in: Pubmed

Prediction Model for Tumor Volume Nadir in EGFR -mutant NSCLC Patients Treated With EGFR Tyrosine Kinase Inhibitors. J Thorac Imaging. 2023 Mar 01; 38(2):82-87. View in: Pubmed

Phase 2 Study of Dabrafenib Plus Trametinib in Patients With BRAF V600E-Mutant Metastatic NSCLC: Updated 5-Year Survival Rates and Genomic Analysis. J Thorac Oncol. 2022 01; 17(1):103-115. View in: Pubmed

Spatially organized multicellular immune hubs in human colorectal cancer. Cell. 2021 09 02; 184(18):4734-4752.e20. View in: Pubmed

Performance of a Machine Learning Algorithm Using Electronic Health Record Data to Identify and Estimate Survival in a Longitudinal Cohort of Patients With Lung Cancer. JAMA Netw Open. 2021 07 01; 4(7):e2114723. View in: Pubmed

Knowledge and Practice Patterns Among Pulmonologists for Molecular Biomarker Testing in Advanced Non-small Cell Lung Cancer. Chest. 2021 12; 160(6):2293-2303. View in: Pubmed

Association between Smoking History and Tumor Mutation Burden in Advanced Non-Small Cell Lung Cancer. Cancer Res. 2021 05 01; 81(9):2566-2573. View in: Pubmed

Multimodal pooled Perturb-CITE-seq screens in patient models define mechanisms of cancer immune evasion. Nat Genet. 2021 03; 53(3):332-341. View in: Pubmed

Expansion sequencing: Spatially precise in situ transcriptomics in intact biological systems. Science. 2021 01 29; 371(6528). View in: Pubmed

Genomic Characterization of de novo Metastatic Breast Cancer. Clin Cancer Res. 2021 02 15; 27(4):1105-1118. View in: Pubmed

Clinical Pan-Cancer Assessment of Mismatch Repair Deficiency Using Tumor-Only, Targeted Next-Generation Sequencing. JCO Precis Oncol. 2020 Nov; 4:1084-1097. View in: Pubmed

Natural Language Processing to Ascertain Cancer Outcomes From Medical Oncologist Notes. JCO Clin Cancer Inform. 2020 08; 4:680-690. View in: Pubmed

Author Correction: A single-cell and single-nucleus RNA-Seq toolbox for fresh and frozen human tumors. Nat Med. 2020 Aug; 26(8):1307. View in: Pubmed

A single-cell landscape of high-grade serous ovarian cancer. Nat Med. 2020 08; 26(8):1271-1279. View in: Pubmed

A single-cell and single-nucleus RNA-Seq toolbox for fresh and frozen human tumors. Nat Med. 2020 05; 26(5):792-802. View in: Pubmed

The Human Tumor Atlas Network: Charting Tumor Transitions across Space and Time at Single-Cell Resolution. Cell. 2020 04 16; 181(2):236-249. View in: Pubmed

Genomic characterization of human brain metastases identifies drivers of metastatic lung adenocarcinoma. Nat Genet. 2020 04; 52(4):371-377. View in: Pubmed

Tumor Volume Analysis as a Predictive Marker for Prolonged Survival in Anaplastic Lymphoma Kinase-rearranged Advanced Non-Small Cell Lung Cancer Patients Treated With Crizotinib. J Thorac Imaging. 2020 Mar; 35(2):101-107. View in: Pubmed

Tumor volume dynamics and tumor growth rate in ALK-rearranged advanced non-small-cell lung cancer treated with crizotinib. Eur J Radiol Open. 2020; 7:100210. View in: Pubmed

The impact of quantitative CT-based tumor volumetric features on the outcomes of patients with limited stage small cell lung cancer. Radiat Oncol. 2020 Jan 14; 15(1):14. View in: Pubmed

From clinical specimens to human cancer preclinical models-a journey the NCI-cell line database-25 years later. J Cell Biochem. 2019 Dec 05. View in: Pubmed

Identifying ERBB2 Activating Mutations in HER2-Negative Breast Cancer: Clinical Impact of Institute-Wide Genomic Testing and Enrollment in Matched Therapy Trials. JCO Precis Oncol. 2019; 3. View in: Pubmed

Assessment of Deep Natural Language Processing in Ascertaining Oncologic Outcomes From Radiology Reports. JAMA Oncol. 2019 Oct 01; 5(10):1421-1429. View in: Pubmed

MET IHC Is a Poor Screen for MET Amplification or MET Exon 14 Mutations in Lung Adenocarcinomas: Data from a Tri-Institutional Cohort of the Lung Cancer Mutation Consortium. J Thorac Oncol. 2019 09; 14(9):1666-1671. View in: Pubmed

Race, Poverty, and Initial Implementation of Precision Medicine for Lung Cancer. J Natl Cancer Inst. 2019 04 01; 111(4):431-434. View in: Pubmed

Interstitial lung abnormality in stage IV non-small cell lung cancer: A validation study for the association with poor clinical outcome. Eur J Radiol Open. 2019; 6:128-131. View in: Pubmed

Use of targeted next generation sequencing to characterize tumor mutational burden and efficacy of immune checkpoint inhibition in small cell lung cancer. J Immunother Cancer. 2019 03 28; 7(1):87. View in: Pubmed

Characteristics and Outcomes of Patients With Metastatic KRAS-Mutant Lung Adenocarcinomas: The Lung Cancer Mutation Consortium Experience. J Thorac Oncol. 2019 05; 14(5):876-889. View in: Pubmed

Clinical Cancer Advances 2019: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. J Clin Oncol. 2019 04 01; 37(10):834-849. View in: Pubmed

M1b Disease in the 8th Edition of TNM Staging of Lung Cancer: Pattern of Single Extrathoracic Metastasis and Clinical Outcome. Oncologist. 2019 08; 24(8):e749-e754. View in: Pubmed

Real-world treatment patterns and survival of patients with BRAF V600-mutated metastatic non-small cell lung cancer. Lung Cancer. 2019 02; 128:74-90. View in: Pubmed

Outcomes by EGFR, KRAS, and ALK Genotype After Combined Modality Therapy for Locally Advanced Non-Small-Cell Lung Cancer. JCO Precis Oncol. 2018 Nov; 2:1-18. View in: Pubmed

A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade. Cell. 2018 11 01; 175(4):984-997.e24. View in: Pubmed

Automated image analysis tool for tumor volume growth rate to guide precision cancer therapy: EGFR-mutant non-small-cell lung cancer as a paradigm. Eur J Radiol. 2018 Dec; 109:68-76. View in: Pubmed

Success of genomic profiling of non-small cell lung cancer biopsies obtained by trans-thoracic percutaneous needle biopsy. J Surg Oncol. 2018 Dec; 118(7):1170-1177. View in: Pubmed

Impact of BRAF Mutation Class on Disease Characteristics and Clinical Outcomes in BRAF-mutant Lung Cancer. Clin Cancer Res. 2019 01 01; 25(1):158-165. View in: Pubmed

2018 ASCO Presidential Address: "Delivering Discoveries: Expanding the Reach of Precision Medicine". J Clin Oncol. 2018 10 10; 36(29):2899-2903. View in: Pubmed

Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine. Cancer Discov. 2018 09; 8(9):1096-1111. View in: Pubmed

A Phase I Trial of Surgical Resection and Intraoperative Hyperthermic Cisplatin and Gemcitabine for Pleural Mesothelioma. J Thorac Oncol. 2018 09; 13(9):1400-1409. View in: Pubmed

BRAF Adds an Additional Piece of the Puzzle to Precision Oncology-Based Treatment Strategies in Lung Cancer. Arch Pathol Lab Med. 2018 07; 142(7):796-797. View in: Pubmed

The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations-The Lung Cancer Mutation Consortium (LCMC2). Clin Cancer Res. 2018 03 01; 24(5):1038-1047. View in: Pubmed

Expanding the Reach of Targeted Therapy in Lung Cancer. Ann Oncol. 2017 Oct; 28 Suppl 9:ix5. View in: Pubmed

Training oncologists to carry out clinical trials. Ann Oncol. 2017 Oct; 28 Suppl 9:ix1. View in: Pubmed

Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial. Lancet Oncol. 2017 10; 18(10):1307-1316. View in: Pubmed

HER2 mutations in lung adenocarcinomas: A report from the Lung Cancer Mutation Consortium. Cancer. 2017 Nov 01; 123(21):4099-4105. View in: Pubmed

An open-label, phase II study of the polo-like kinase-1 (Plk-1) inhibitor, BI 2536, in patients with relapsed small cell lung cancer (SCLC). Lung Cancer. 2017 02; 104:126-130. View in: Pubmed

Co-clinical quantitative tumor volume imaging in ALK-rearranged NSCLC treated with crizotinib. Eur J Radiol. 2017 Mar; 88:15-20. View in: Pubmed

Institutional implementation of clinical tumor profiling on an unselected cancer population. JCI Insight. 2016 11 17; 1(19):e87062. View in: Pubmed

Divide and Conquer to Treat Lung Cancer. N Engl J Med. 2016 11 10; 375(19):1892-1893. View in: Pubmed

Prospective Study of Repeated Biopsy Feasibility and Acquired Resistance at Disease Progression in Patients With Advanced EGFR Mutant Lung Cancer Treated With Erlotinib in a Phase 2 Trial. JAMA Oncol. 2016 Sep 01; 2(9):1240-2. View in: Pubmed

Identification of Existing Drugs That Effectively Target NTRK1 and ROS1 Rearrangements in Lung Cancer. Clin Cancer Res. 2017 Jan 01; 23(1):204-213. View in: Pubmed

A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR-Mutant Non-Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial. Clin Cancer Res. 2016 Dec 15; 22(24):6010-6020. View in: Pubmed

Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. Lancet Oncol. 2016 Jul; 17(7):984-993. View in: Pubmed

Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial. Lancet Oncol. 2016 05; 17(5):642-50. View in: Pubmed

Clinical trial enrollment expansion to the community. J Clin Oncol. 2016 Mar; 34(7_suppl):112. View in: Pubmed

Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. Nat Commun. 2016 Feb 17; 7:10501. View in: Pubmed

Volumetric Tumor Response and Progression in EGFR-mutant NSCLC Patients Treated with Erlotinib or Gefitinib. Acad Radiol. 2016 Mar; 23(3):329-36. View in: Pubmed

Five-Year Survival in EGFR-Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs. J Thorac Oncol. 2016 Apr; 11(4):556-65. View in: Pubmed

Role of race in oncogenic driver prevalence and outcomes in lung adenocarcinoma: Results from the Lung Cancer Mutation Consortium. Cancer. 2016 Mar 01; 122(5):766-72. View in: Pubmed

Emerging gene mutation targets in lung cancer. Clin Adv Hematol Oncol. 2015 Dec; 13(12):812-4. View in: Pubmed

KDR Amplification Is Associated with VEGF-Induced Activation of the mTOR and Invasion Pathways but does not Predict Clinical Benefit to the VEGFR TKI Vandetanib. Clin Cancer Res. 2016 Apr 15; 22(8):1940-50. View in: Pubmed

Detection of T790M, the Acquired Resistance EGFR Mutation, by Tumor Biopsy versus Noninvasive Blood-Based Analyses. Clin Cancer Res. 2016 Mar 01; 22(5):1103-10. View in: Pubmed

Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. Cancer Discov. 2015 Nov; 5(11):1164-1177. View in: Pubmed

Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience. J Thorac Oncol. 2015 May; 10(5):768-777. View in: Pubmed

Delay of treatment change after objective progression on first-line erlotinib in epidermal growth factor receptor-mutant lung cancer. Cancer. 2015 Aug 01; 121(15):2570-7. View in: Pubmed

A phase I trial of high dose gefitinib for patients with leptomeningeal metastases from non-small cell lung cancer. Oncotarget. 2015 Feb 28; 6(6):4527-36. View in: Pubmed

Interstitial lung abnormalities in treatment-naïve advanced non-small-cell lung cancer patients are associated with shorter survival. Eur J Radiol. 2015 May; 84(5):998-1004. View in: Pubmed

Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium. Cancer. 2015 Feb 01; 121(3):448-56. View in: Pubmed

Biomarker analyses from a randomized, placebo-controlled, phase IIIb trial comparing bevacizumab with or without erlotinib as maintenance therapy for the treatment of advanced non-small-cell lung cancer (ATLAS). J Thorac Oncol. 2014 Sep; 9(9):1411-7. View in: Pubmed

Chemotherapy for locally advanced and metastatic pulmonary carcinoid tumors. Lung Cancer. 2014 Nov; 86(2):241-6. View in: Pubmed

Realizing the potential of plasma genotyping in an age of genotype-directed therapies. J Natl Cancer Inst. 2014 Aug; 106(8). View in: Pubmed

Evaluation of statistical designs in phase I expansion cohorts: the Dana-Farber/Harvard Cancer Center experience. J Natl Cancer Inst. 2014 Jul; 106(7). View in: Pubmed

Definitive primary therapy in patients presenting with oligometastatic non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2014 Jul 15; 89(4):880-7. View in: Pubmed

Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA. 2014 May 21; 311(19):1998-2006. View in: Pubmed

State of the art: Response assessment in lung cancer in the era of genomic medicine. Radiology. 2014 Apr; 271(1):6-27. View in: Pubmed

Treatment-related toxicities in a phase II trial of dasatinib in patients with squamous cell carcinoma of the lung. J Thorac Oncol. 2013 Nov; 8(11):1434-7. View in: Pubmed

ATLAS: randomized, double-blind, placebo-controlled, phase IIIB trial comparing bevacizumab therapy with or without erlotinib, after completion of chemotherapy, with bevacizumab for first-line treatment of advanced non-small-cell lung cancer. J Clin Oncol. 2013 Nov 01; 31(31):3926-34. View in: Pubmed

The impact of genomic changes on treatment of lung cancer. Am J Respir Crit Care Med. 2013 Oct 01; 188(7):770-5. View in: Pubmed

Cetuximab response of lung cancer-derived EGF receptor mutants is associated with asymmetric dimerization. Cancer Res. 2013 Nov 15; 73(22):6770-9. View in: Pubmed

Volumetric tumor growth in advanced non-small cell lung cancer patients with EGFR mutations during EGFR-tyrosine kinase inhibitor therapy: developing criteria to continue therapy beyond RECIST progression. Cancer. 2013 Nov 01; 119(21):3761-8. View in: Pubmed

Tumor volume decrease at 8 weeks is associated with longer survival in EGFR-mutant advanced non-small-cell lung cancer patients treated with EGFR TKI. J Thorac Oncol. 2013 Aug; 8(8):1059-68. View in: Pubmed

Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer. Clin Cancer Res. 2013 Aug 15; 19(16):4532-40. View in: Pubmed

RECIST 1.1 in NSCLC patients with EGFR mutations treated with EGFR tyrosine kinase inhibitors: comparison with RECIST 1.0. AJR Am J Roentgenol. 2013 Jul; 201(1):W64-71. View in: Pubmed

Meta-analysis of EGFR kinase inhibitors: not always greater than the sum of its parts. J Natl Cancer Inst. 2013 May 01; 105(9):589-90. View in: Pubmed

Comparative effectiveness of three platinum-doublet chemotherapy regimens in elderly patients with advanced non-small cell lung cancer. Cancer. 2013 Jun 01; 119(11):2048-60. View in: Pubmed

Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions. J Thorac Oncol. 2013 Feb; 8(2):179-84. View in: Pubmed

Radiographic assessment and therapeutic decisions at RECIST progression in EGFR-mutant NSCLC treated with EGFR tyrosine kinase inhibitors. Lung Cancer. 2013 Mar; 79(3):283-8. View in: Pubmed

The introduction of systematic genomic testing for patients with non-small-cell lung cancer. J Thorac Oncol. 2012 Dec; 7(12):1767-1774. View in: Pubmed

Everolimus and erlotinib as second- or third-line therapy in patients with advanced non-small-cell lung cancer. J Thorac Oncol. 2012 Oct; 7(10):1594-601. View in: Pubmed

ACP Journal Club. Review: teriparatide reduces fractures in postmenopausal women with osteoporosis. Ann Intern Med. 2012 Sep 18; 157(6):JC3-4. View in: Pubmed

Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell. 2012 Sep 14; 150(6):1107-20. View in: Pubmed

Comprehensive genomic characterization of squamous cell lung cancers. Nature. 2012 Sep 27; 489(7417):519-25. View in: Pubmed

Unsuspected pulmonary embolism in lung cancer patients: comparison of clinical characteristics and outcome with suspected pulmonary embolism. Lung Cancer. 2012 Nov; 78(2):161-6. View in: Pubmed

Chapter 9: The MGH-HMS lung cancer policy model: tobacco control versus screening. Risk Anal. 2012 Jul; 32 Suppl 1:S117-24. View in: Pubmed

Tumoral cavitation in patients with non-small-cell lung cancer treated with antiangiogenic therapy using bevacizumab. Cancer Imaging. 2012 Jun 29; 12:225-35. View in: Pubmed

The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non-small cell lung cancer with EGFR mutations. Clin Cancer Res. 2012 Aug 15; 18(16):4406-14. View in: Pubmed

Adjuvant chemotherapy for surgically resected non-small cell lung cancer. J Thorac Cardiovasc Surg. 2012 Sep; 144(3):S39-42. View in: Pubmed

Making personalized cancer medicine a reality: challenges and opportunities in the development of biomarkers and companion diagnostics. Clin Cancer Res. 2012 Feb 01; 18(3):619-24. View in: Pubmed

A pulmonary hypertension gas exchange severity (PH-GXS) score to assist with the assessment and monitoring of pulmonary arterial hypertension. Am J Cardiol. 2012 Apr 01; 109(7):1066-72. View in: Pubmed

Factors associated with smoking abstinence among smokers and recent-quitters with lung and head and neck cancer. Lung Cancer. 2012 May; 76(2):144-9. View in: Pubmed

Cost-effectiveness of computed tomography screening for lung cancer in the United States. J Thorac Oncol. 2011 Nov; 6(11):1841-8. View in: Pubmed

Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discov. 2011 Jun; 1(1):78-89. View in: Pubmed

The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov. 2011 Jun; 1(1):44-53. View in: Pubmed

International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol. 2011 Feb; 6(2):244-85. View in: Pubmed

Imaging of lung cancer in the era of molecular medicine. Acad Radiol. 2011 Apr; 18(4):424-36. View in: Pubmed

Patient-reported receipt of and interest in smoking-cessation interventions after a diagnosis of cancer. Cancer. 2011 Jul 01; 117(13):2961-9. View in: Pubmed

CT tumor volume measurement in advanced non-small-cell lung cancer: Performance characteristics of an emerging clinical tool. Acad Radiol. 2011 Jan; 18(1):54-62. View in: Pubmed

Submaximal exercise gas exchange is an important prognostic tool to predict adverse outcomes in heart failure. Eur J Heart Fail. 2011 Mar; 13(3):303-10. View in: Pubmed

Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib. Clin Cancer Res. 2010 Dec 01; 16(23):5873-82. View in: Pubmed

New Response Evaluation Criteria in Solid Tumors (RECIST) guidelines for advanced non-small cell lung cancer: comparison with original RECIST and impact on assessment of tumor response to targeted therapy. AJR Am J Roentgenol. 2010 Sep; 195(3):W221-8. View in: Pubmed

Virginia Tech Carilion School of Medicine and Research Institute. Acad Med. 2010 Sep; 85(9 Suppl):S582-5. View in: Pubmed

Haplotypes of estrogen receptor-beta and risk of non-small cell lung cancer in women. Lung Cancer. 2011 Mar; 71(3):258-63. View in: Pubmed

Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. Lancet Oncol. 2010 Jul; 11(7):619-26. View in: Pubmed

A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry. Clin Cancer Res. 2010 Mar 01; 16(5):1561-71. View in: Pubmed

ACP Journal Club. Estrogen plus progestin increased lung cancer mortality but not incidence in postmenopausal women. Ann Intern Med. 2010 Feb 16; 152(4):JC-28. View in: Pubmed

Parity and risk of lung cancer in women. Am J Epidemiol. 2010 Mar 01; 171(5):557-63. View in: Pubmed

Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer. Clin Cancer Res. 2009 Dec 15; 15(24):7502-7509. View in: Pubmed

The Intermountain Risk Score, based on common laboratory tests, was highly predictive of short-term mortality. Evid Based Med. 2009 Dec; 14(6):186. View in: Pubmed

Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung cancer. J Clin Oncol. 2010 Jan 10; 28(2):193-201. View in: Pubmed

Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. J Clin Oncol. 2010 Jan 10; 28(2):357-60. View in: Pubmed

Outcomes of patients with stage III nonsmall cell lung cancer treated with chemotherapy and radiation with and without surgery. Cancer. 2009 Sep 15; 115(18):4156-66. View in: Pubmed

Phase I study of the c-raf-1 antisense oligonucleotide ISIS 5132 in combination with carboplatin and paclitaxel in patients with previously untreated, advanced non-small cell lung cancer. J Thorac Oncol. 2009 Sep; 4(9):1156-62. View in: Pubmed

Integration of molecular profiling into the lung cancer clinic. Clin Cancer Res. 2009 Sep 01; 15(17):5317-22. View in: Pubmed

Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res. 2009 Aug 15; 15(16):5216-23. View in: Pubmed

Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials. Clin Cancer Res. 2009 Aug 15; 15(16):5267-73. View in: Pubmed

Clinical significance of TTF-1 protein expression and TTF-1 gene amplification in lung adenocarcinoma. J Cell Mol Med. 2009 Aug; 13(8B):1977-1986. View in: Pubmed

Extrapleural pneumonectomy followed by intracavitary intraoperative hyperthermic cisplatin with pharmacologic cytoprotection for treatment of malignant pleural mesothelioma: a phase II prospective study. J Thorac Cardiovasc Surg. 2009 Aug; 138(2):405-11. View in: Pubmed

ACP Journal Club. Postmenopausal hormone therapy was cost-effective when started at age 50 years but not at 65 years. Ann Intern Med. 2009 Jun 16; 150(12):JC6-15. View in: Pubmed

Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance. Clin Cancer Res. 2009 May 15; 15(10):3484-94. View in: Pubmed

Baseline vascular endothelial growth factor concentration as a potential predictive marker of benefit from vandetanib in non-small cell lung cancer. Clin Cancer Res. 2009 May 15; 15(10):3600-9. View in: Pubmed

Predictive value of heart rate recovery and peak oxygen consumption for long-term mortality in patients with coronary heart disease. Am J Cardiol. 2009 Jun 15; 103(12):1641-6. View in: Pubmed

A phase I study of extrapleural pneumonectomy and intracavitary intraoperative hyperthermic cisplatin with amifostine cytoprotection for malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 2009 Feb; 137(2):453-8. View in: Pubmed

Impact of graft volume reduction for oversized grafts after lung transplantation on outcome in recipients with end-stage restrictive pulmonary diseases. J Heart Lung Transplant. 2009 Feb; 28(2):130-4. View in: Pubmed

Adopting helical CT screening for lung cancer: potential health consequences during a 15-year period. Cancer. 2008 Dec 15; 113(12):3440-9. View in: Pubmed

Autocrine production of amphiregulin predicts sensitivity to both gefitinib and cetuximab in EGFR wild-type cancers. Clin Cancer Res. 2008 Nov 01; 14(21):6963-73. View in: Pubmed

Somatic mutations affect key pathways in lung adenocarcinoma. Nature. 2008 Oct 23; 455(7216):1069-75. View in: Pubmed

Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol. 2008 Nov 20; 26(33):5407-15. View in: Pubmed

Immunohistochemical markers associated with brain metastases in patients with nonsmall cell lung carcinoma. Cancer. 2008 Oct 15; 113(8):2129-38. View in: Pubmed

Long-term outcome of lung and heart-lung transplantation for idiopathic pulmonary arterial hypertension. Ann Thorac Surg. 2008 Oct; 86(4):1116-22. View in: Pubmed

Heart rate recovery and prognosis in heart failure patients. Eur J Appl Physiol. 2009 Jan; 105(1):37-45. View in: Pubmed

Gefitinib for recurrent non-small-cell lung cancer: all things are not created equal. J Clin Oncol. 2008 Sep 10; 26(26):4233-5. View in: Pubmed

Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma. Cancer. 2008 Aug 15; 113(4):808-14. View in: Pubmed

Long-term mortality with multiple treadmill exercise test abnormalities: comparison between patients with and without cardiovascular disease. Am Heart J. 2008 Oct; 156(4):783-9. View in: Pubmed

Estimating long-term effectiveness of lung cancer screening in the Mayo CT screening study. Radiology. 2008 Jul; 248(1):278-87. View in: Pubmed

First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol. 2008 May 20; 26(15):2442-9. View in: Pubmed

Preoperative evaluation of the gynecologic patient: considerations for improved outcomes. Obstet Gynecol. 2008 May; 111(5):1183-94. View in: Pubmed

Leptin, a novel predictor of lung function in heart failure. Chest. 2008 Aug; 134(2):346-350. View in: Pubmed

Human phenylethanolamine N-methyltransferase genetic polymorphisms and exercise-induced epinephrine release. Physiol Genomics. 2008 May 13; 33(3):323-32. View in: Pubmed

Small cell lung cancer. J Natl Compr Canc Netw. 2008 Mar; 6(3):294-314. View in: Pubmed

Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial setting. J Clin Oncol. 2008 Feb 20; 26(6):983-94. View in: Pubmed

Civic norms and etiquettes regarding marijuana use in public settings in New York City. Subst Use Misuse. 2008; 43(7):895-918. View in: Pubmed

Family medicine practice in rural any-country. Fam Med. 2008 Jan; 40(1):55-6. View in: Pubmed

Characterizing the cancer genome in lung adenocarcinoma. Nature. 2007 Dec 06; 450(7171):893-8. View in: Pubmed

Efficacy and safety of single-agent pertuzumab, a human epidermal receptor dimerization inhibitor, in patients with non small cell lung cancer. Clin Cancer Res. 2007 Oct 15; 13(20):6175-81. View in: Pubmed

Right ventricular function with hypoxic exercise: effects of sildenafil. Eur J Appl Physiol. 2007 Dec; 102(1):87-95. View in: Pubmed

A once yearly IV infusion of zoledronic acid prevented fractures in postmenopausal women with osteoporosis. Evid Based Med. 2007 Oct; 12(5):145. View in: Pubmed

Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer. J Clin Oncol. 2007 Sep 20; 25(27):4270-7. View in: Pubmed

A once-yearly IV infusion of zoledronic acid prevented fractures in postmenopausal women with osteoporosis. ACP J Club. 2007 Sep-Oct; 147(2):31. View in: Pubmed

LKB1 modulates lung cancer differentiation and metastasis. Nature. 2007 Aug 16; 448(7155):807-10. View in: Pubmed

Novel agents in the treatment of lung cancer: Fourth Cambridge Conference. Clin Cancer Res. 2007 Aug 01; 13(15 Pt 2):s4583-8. View in: Pubmed

Rationale for a phase I trial of erlotinib and the mammalian target of rapamycin inhibitor everolimus (RAD001) for patients with relapsed non small cell lung cancer. Clin Cancer Res. 2007 Aug 01; 13(15 Pt 2):s4628-31. View in: Pubmed

Herbal supplements did not relieve vasomotor symptoms of menopause in women. Evid Based Med. 2007 Jun; 12(3):78. View in: Pubmed

Mutations in BRAF and KRAS converge on activation of the mitogen-activated protein kinase pathway in lung cancer mouse models. Cancer Res. 2007 May 15; 67(10):4933-9. View in: Pubmed

Herbal supplements did not relieve vasomotor symptoms of menopause. ACP J Club. 2007 May-Jun; 146(3):65. View in: Pubmed

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science. 2007 May 18; 316(5827):1039-43. View in: Pubmed

Pulmonary function changes associated with cardiomegaly in chronic heart failure. J Card Fail. 2007 Mar; 13(2):100-7. View in: Pubmed

Arginine 16 glycine beta2-adrenoceptor polymorphism and cardiovascular structure and function in patients with heart failure. J Am Soc Echocardiogr. 2007 Mar; 20(3):290-7. View in: Pubmed

A phase II study of the safety and efficacy of the multidrug resistance inhibitor VX-710 combined with doxorubicin and vincristine in patients with recurrent small cell lung cancer. Cancer. 2007 Mar 01; 109(5):924-32. View in: Pubmed

Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer. J Clin Oncol. 2007 Mar 01; 25(7):760-6. View in: Pubmed

Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testing. Oncologist. 2007 Jan; 12(1):90-8. View in: Pubmed

Bronchioloalveolar carcinoma and lung adenocarcinoma: the clinical importance and research relevance of the 2004 World Health Organization pathologic criteria. J Thorac Oncol. 2006 Nov; 1(9 Suppl):S13-9. View in: Pubmed

Beta2-adrenergic receptor genotype and pulmonary function in patients with heart failure. Chest. 2006 Nov; 130(5):1527-34. View in: Pubmed

Molecular biology, genomics, and proteomics in bronchioloalveolar carcinoma. J Thorac Oncol. 2006 Nov; 1(9 Suppl):S8-12. View in: Pubmed

Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib. J Clin Oncol. 2006 Sep 20; 24(27):4517-20. View in: Pubmed

Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer. J Clin Invest. 2006 Oct; 116(10):2695-706. View in: Pubmed

Rationale for a phase II trial of pertuzumab, a HER-2 dimerization inhibitor, in patients with non-small cell lung cancer. Clin Cancer Res. 2006 Jul 15; 12(14 Pt 2):4436s-4440s. View in: Pubmed

Epidermal growth factor receptor mutation testing in the care of lung cancer patients. Clin Cancer Res. 2006 Jul 15; 12(14 Pt 2):4403s-4408s. View in: Pubmed

Summary statement: novel agents in the treatment of lung cancer: advances in epidermal growth factor receptor-targeted agents. Clin Cancer Res. 2006 Jul 15; 12(14 Pt 2):4365s-4371s. View in: Pubmed

Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors. Clin Cancer Res. 2006 Jul 15; 12(14 Pt 2):4416s-4420s. View in: Pubmed

Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Clin Cancer Res. 2006 Jul 01; 12(13):3908-14. View in: Pubmed

Small cell lung cancer clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2006 Jul; 4(6):602-22. View in: Pubmed

Paraneoplastic syndromes associated with small cell lung cancer. J Natl Compr Canc Netw. 2006 Jul; 4(6):631-8. View in: Pubmed

Oestrogen did not improve health related quality of life in postmenopausal women with hysterectomy. Evid Based Med. 2006 Jun; 11(3):76. View in: Pubmed

The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. Cancer Cell. 2006 Jun; 9(6):485-95. View in: Pubmed

The Arg16Gly polymorphism of the beta2-adrenergic receptor and the natriuretic response to rapid saline infusion in humans. J Physiol. 2006 Aug 01; 574(Pt 3):947-54. View in: Pubmed

A rapid and sensitive enzymatic method for epidermal growth factor receptor mutation screening. Clin Cancer Res. 2006 Feb 01; 12(3 Pt 1):751-8. View in: Pubmed

A metabolic study of patients with lung cancer and hyponatremia of malignancy. Clin Cancer Res. 2006 Feb 01; 12(3 Pt 1):888-96. View in: Pubmed

Clinical Cancer Advances 2005: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol. 2006 Jan 01; 24(1):190-205. View in: Pubmed

Left atrial index is a predictor of exercise capacity in patients with hypertrophic cardiomyopathy. J Am Soc Echocardiogr. 2005 Dec; 18(12):1373-80. View in: Pubmed

Inhibition of the met receptor in mesothelioma. Clin Cancer Res. 2005 Nov 15; 11(22):8122-30. View in: Pubmed

Update: NCCN small cell and non-small cell lung cancer Clinical Practice Guidelines. J Natl Compr Canc Netw. 2005 Nov; 3 Suppl 1:S17-21. View in: Pubmed

The pulmonary status of patients with limited-stage small cell lung cancer 15 years after treatment with chemotherapy and chest irradiation. Chest. 2005 Nov; 128(5):3261-8. View in: Pubmed

Small-cell lung cancer. Lancet. 2005 Oct 15-21; 366(9494):1385-96. View in: Pubmed

Selecting patients for epidermal growth factor receptor inhibitor treatment: A FISH story or a tale of mutations? J Clin Oncol. 2005 Oct 01; 23(28):6813-6. View in: Pubmed

Epidermal growth factor receptor mutations in patients with non-small cell lung cancer. Cancer Res. 2005 Sep 01; 65(17):7525-9. View in: Pubmed

Statistic on life expectancy challenged. Postgrad Med. 2005 Sep; 118(3):1; author reply 1-2. View in: Pubmed

Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations. J Natl Cancer Inst. 2005 Aug 17; 97(16):1185-94. View in: Pubmed

Early outcomes in human lung transplantation with Thymoglobulin or Campath-1H for recipient pretreatment followed by posttransplant tacrolimus near-monotherapy. J Thorac Cardiovasc Surg. 2005 Aug; 130(2):528-37. View in: Pubmed

TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol. 2005 Sep 01; 23(25):5892-9. View in: Pubmed

Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol. 2005 Sep 01; 23(25):5900-9. View in: Pubmed

Therapeutic targeting of multiple signaling pathways in malignant pleural mesothelioma. Oncology. 2005; 68(4-6):500-10. View in: Pubmed

Early stage lung cancer--new approaches to evaluation and treatment: conference summary statement. Clin Cancer Res. 2005 Jul 01; 11(13 Pt 2):4981s-4983s. View in: Pubmed

Patient subsets benefiting from adjuvant therapy following surgical resection of non-small cell lung cancer. Clin Cancer Res. 2005 Jul 01; 11(13 Pt 2):5022s-5026s. View in: Pubmed

Immunization with mutant p53- and K-ras-derived peptides in cancer patients: immune response and clinical outcome. J Clin Oncol. 2005 Aug 01; 23(22):5099-107. View in: Pubmed

Effects of beta-blocker therapy on ventilatory responses to exercise in patients with heart failure. J Card Fail. 2005 Jun; 11(5):333-9. View in: Pubmed

Sunburn and swelling: the edema of erythema. South Med J. 2005 Jun; 98(6):672. View in: Pubmed

Evolving concepts in the pathology and computed tomography imaging of lung adenocarcinoma and bronchioloalveolar carcinoma. J Clin Oncol. 2005 May 10; 23(14):3279-87. View in: Pubmed

Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology. J Clin Oncol. 2005 May 10; 23(14):3227-34. View in: Pubmed

Phase I trial of the matrix metalloproteinase inhibitor marimastat combined with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer. Clin Cancer Res. 2005 May 01; 11(9):3417-24. View in: Pubmed

Differential effects of vascular endothelial growth factor receptor-2 inhibitor ZD6474 on circulating endothelial progenitors and mature circulating endothelial cells: implications for use as a surrogate marker of antiangiogenic activity. Clin Cancer Res. 2005 May 01; 11(9):3514-22. View in: Pubmed

Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. Clin Cancer Res. 2005 Apr 15; 11(8):2785-808. View in: Pubmed

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med. 2005 Feb 24; 352(8):786-92. View in: Pubmed

ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines. Proc Natl Acad Sci U S A. 2005 Mar 08; 102(10):3788-93. View in: Pubmed

Plasma leptin and prognosis in patients with established coronary atherosclerosis. J Am Coll Cardiol. 2004 Nov 02; 44(9):1819-24. View in: Pubmed

Review: prophylactic use of Vitamin D reduces falls in older persons. ACP J Club. 2004 Nov-Dec; 141(3):66. View in: Pubmed

Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255. Cancer Res. 2004 Oct 15; 64(20):7241-4. View in: Pubmed

Novel agents in the treatment of lung cancer: conference summary statement. Clin Cancer Res. 2004 Jun 15; 10(12 Pt 2):4199s-4204s. View in: Pubmed

Farnesyl transferase inhibitors for patients with lung cancer. Clin Cancer Res. 2004 Jun 15; 10(12 Pt 2):4254s-4257s. View in: Pubmed

Imatinib for small cell lung cancer, aiming for a target in vivo. Clin Cancer Res. 2004 May 15; 10(10):3235-6. View in: Pubmed

Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, "Iressa") on an expanded access study. Lung Cancer. 2004 May; 44(2):221-30. View in: Pubmed

Outcome of patients with pulmonary carcinoid tumors receiving chemotherapy or chemoradiotherapy. Lung Cancer. 2004 May; 44(2):213-20. View in: Pubmed

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004 Jun 04; 304(5676):1497-500. View in: Pubmed

High-resolution single-nucleotide polymorphism array and clustering analysis of loss of heterozygosity in human lung cancer cell lines. Oncogene. 2004 Apr 08; 23(15):2716-26. View in: Pubmed

Basic treatment considerations using chemotherapy for patients with small cell lung cancer. Hematol Oncol Clin North Am. 2004 Apr; 18(2):309-22. View in: Pubmed

Prospective study of palliative hypofractionated radiotherapy (8.5 Gy x 2) for patients with symptomatic non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2004 Mar 15; 58(4):1098-105. View in: Pubmed

Dietary supplements containing red clover extracts were no better than placebo for hot flashes in menopause. ACP J Club. 2004 Mar-Apr; 140(2):47. View in: Pubmed

Socioeconomic marginality and health services utilization among Central Harlem substance users. Subst Use Misuse. 2004 Jan; 39(1):61-85. View in: Pubmed

Phase II study of imatinib in patients with small cell lung cancer. Clin Cancer Res. 2003 Dec 01; 9(16 Pt 1):5880-7. View in: Pubmed

Prospective study of the airways and pulmonary parenchyma of patients at risk for a second lung cancer. Clin Cancer Res. 2003 Dec 01; 9(16 Pt 1):5915-21. View in: Pubmed

c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. Cancer Res. 2003 Oct 01; 63(19):6272-81. View in: Pubmed

Adjuvant chemotherapy for non-small-cell lung cancer: the end of the beginning. J Natl Cancer Inst. 2003 Oct 01; 95(19):1422-4. View in: Pubmed

Imatinib in small cell lung cancer. Lung Cancer. 2003 Aug; 41 Suppl 1:S49-53. View in: Pubmed

Expression of bcl-2 protein is associated with shorter survival in nonsmall cell lung carcinoma. Cancer. 2003 Jul 01; 98(1):135-43. View in: Pubmed

Induction docetaxel and carboplatin followed by weekly docetaxel and carboplatin with concurrent radiotherapy, then surgery in stage III non-small cell lung cancer: a Phase I study. Clin Cancer Res. 2003 May; 9(5):1698-704. View in: Pubmed

A model to select regimens for phase III trials for patients with advanced-stage non-small cell lung cancer. Clin Cancer Res. 2003 Mar; 9(3):917-22. View in: Pubmed

Sensitivity of non-small-cell lung cancer cell lines established from patients treated with prolonged infusions of Paclitaxel. Oncology. 2003; 64(4):399-406. View in: Pubmed

Regulation of cellular proliferation, cytoskeletal function, and signal transduction through CXCR4 and c-Kit in small cell lung cancer cells. Cancer Res. 2002 Nov 01; 62(21):6304-11. View in: Pubmed

Twenty-five years of clinical research for patients with limited-stage small cell lung carcinoma in North America. Cancer. 2002 Oct 01; 95(7):1528-38. View in: Pubmed

Inhibition of epidermal growth factor receptor signaling in malignant pleural mesothelioma. Cancer Res. 2002 Sep 15; 62(18):5242-7. View in: Pubmed

Phase II neoadjuvant trial of paclitaxel by 96-hour continuous infusion (CIVI) in combination with cisplatin followed by chest radiotherapy for patients with stage III non-small-cell lung cancer. Am J Clin Oncol. 2002 Jun; 25(3):269-73. View in: Pubmed

Management of small cell lung cancer. Clin Chest Med. 2002 Mar; 23(1):225-39. View in: Pubmed

Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer. Clin Cancer Res. 2002 Feb; 8(2):620-7. View in: Pubmed